Nivolumab or pembrolizumab should be added to standard chemotherapy to prolong the life of patients with gastric, esophageal, and gastroesophageal junction cancers.
gastroesophageal junction cancer
Posted inClinical Trials, Oncology
Bemarituzumab: Breakthrough in Gastric Cancer Treatment
A new and effective targeted therapy, being developed by Five Prime Therapeutics and Amgen, for a deadly cancer disease in the past decade.